Clinical Trial Update: Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD [NA]

View source ↗

Summary

A clinical trial investigating ruxolitinib plus etanercept versus ruxolitinib alone for steroid-refractory severe acute graft-versus-host disease is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Etanercept (etanercept)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Graft vs Host Disease | NA | Status: RECRUITING